Table 1.
Cohort demographics and baseline characteristicsa
| HAD− (N = 30) | HAD+ (N = 24) | P valueb | |
|---|---|---|---|
| Gender | |||
| Male | 22 (73%) | 15 (63%) | .39 |
| Female | 8 (27%) | 9 (38%) | |
| Race | |||
| Black | 25 (83%) | 24 (100%) | <.04 |
| White | 5 (17%) | ||
| Age (years) | 40.2 ± 5.9 | 41.4 ± 7.6 | .70 |
| Education (years) | 12.8 ± 2.3 | 11.6 ± 1.5 | .02 |
| MSK | 0.42 ± 0.19 | 1.33 ± 0.48 | <10−10 |
| NPZ-8 (z scores) | −0.79 ± 0.70 | −2.37 ± 0.94 | <10−7 |
| Mode of infection | |||
| IV-drug use | 6 (20%) | 9 (38%) | .18 |
| Sexual contact | 19 (63%) | 8 (33%) | |
| Sexual contact/IV-drug use | 1 (3%) | 2 (8%) | |
| Transfusion | 1 (3%) | 0 (0%) | |
| Unknown | 3 (10%) | 5 (21%) | |
| CD4+ T cells (cells/µl) | 179 ± 166 | 162 ± 136 | .77 |
| AIDS (CD4 <200) | |||
| Yes | 19 (68%) | 15 (65%) | .84 |
| No | 9 (32%) | 8 (35%) | |
| Viral load (log10 copies/ml) | |||
| Plasma | 4.86 ± 0.55 | 4.82 ± 0.71 | .96 |
| CSF | 3.69 ± 0.92 | 3.22 ± 0.82 | <.07 |
| M-CSF (ng/ml) | |||
| Plasma | 2.02 ± 1.78 | 2.08 ± 1.02 | .17 |
| CSF | 1.20 ± 1.43 | 2.05 ± 1.66 | <.02 |
| Therapy regimenc | |||
| At least 2 NRTIs | |||
| Yes | 20 (95%) | 18 (100%) | .75 |
| No | 1 (5%) | ||
| At least 1 protease inhibitor | |||
| Yes | 9 (43%) | 7 (39%) | .80 |
| No | 12 (57%) | 11 (61%) | |
| Highly active ART | |||
| Yes | 20 (95%) | 18 (100%) | .35 |
| No | 1 (5%) |
a
Values represent mean ± SD or N (%).
b
All categorical variables were compared between dementia groups using a Pearson chi-squared test. All continuous variables were compared between dementia groups using a nonparametric Wilcoxon rank sum test.
c
Description of therapy regimens initiated by the 39 subjects followed for 10 months.